Abstract
Real-world data are limited on use of fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that targets calcitonin gene-related peptide (CGRP), in migraine patients with acute medication overuse (AMO). This retrospective US claims database analysis evaluated migraine-related healthcare resource utilization (HCRU) and costs for patients with potential AMO initiating fremanezumab treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
